A more recent analysis, then, on 278 CBF AML, demonstrated that the persistence or reappearance of RUNX1/RUNX1T1 above 500/104 ABL copies in BM, or above 100/104 ABL copies in PB, after consolidation therapy or during follow-up, were associated with certain hematological relapse [27]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.